Targeting CD47 for cancer immunotherapy - PMC
2021年10月30日 · Much progress has been made in targeting CD47 for cancer immunotherapy in solid tumors (ST) and hematological malignancies. We summarized the CD47-related clinical research and analyzed the research trend both in the USA and in China.
CD47: role in the immune system and application to cancer ...
Here, we review the role of CD47 in the maintenance of immune system homeostasis. We also depict three emerging CD47-targeting strategies for cancer therapy, including the use of mimicry peptides, antibodies, and gene silencing strategies.
Role of CD47 in tumor immunity: a potential target for ...
2022年6月13日 · CD47 is a novel potent immunotherapy target in malignancies, targeting CD47 may be a novel strategy for cancer immunotherapy. A variety of studies have verified the synergistic effect of...
Opportunities and challenges of CD47-targeted therapy in ...
2023年11月15日 · CD47 is expressed on many different types of cancer cells, making it a potentially broad target for cancer treatment. In summary, CD47-targeted therapies offer a promising opportunity to enhance anti-tumor immunity …
The landscape overview of CD47-based immunotherapy for ...
2023年2月1日 · Increasing evidence demonstrates that blocking CD47 interaction with SIRPα can enhance cancer cell clearance by macrophages. Additionally, inhibition of CD47/SIRPα interaction can increase antigen cross-presentation, leading to T-cell priming and an activated adaptive antitumor immune response.
Emerging phagocytosis checkpoints in cancer immunotherapy
2023年3月7日 · Phagocytosis checkpoints, such as CD47, CD24, MHC-I, PD-L1, STC-1 and GD2, have emerged as essential checkpoints for cancer immunotherapy by functioning as “don’t eat me” signals or ...
Deciphering the role of CD47 in cancer immunotherapy
2024年9月1日 · The Cluster of Differentiation 47 (CD47) has emerged as a crucial checkpoint for cancer immunotherapy by working as a “don’t eat me” signal and suppressing innate immune signaling. Furthermore, CD47 is highly expressed in many cancer types to protect cancer cells from phagocytosis via binding to SIRPα on phagocytes.